Rocket inks Renovacor buyout to propel its heart disease gene therapy ambitions

Rocket Pharmaceuticals is set to snap up gene therapy startup Renovacor, inking an all-stock merger that will give it control of a preclinical heart disease candidate and add $38 million to its cash reserves.